Stanford researchers have engineered chimeric cytokine receptors that are expressed in therapeutic cells to enhance their activity and therapeutic potential.
Many applications in cell therapy, synthetic biology, and gene therapy require extensive cell engineering, often with multiple vectors due to limitations in packaging capacity.
A team of Stanford researchers has identified a group of small molecules that can prevent or reverse T cell exhaustion, thereby increasing the effectiveness of adoptive T cell therapies to fight cancer or chronic infections.
A Stanford research team has patented methods that can prevent or reverse T cell exhaustion, thereby increasing the effectiveness of adoptive T cell therapies to fight cancer or chronic infections.
The potency of cancer immunotherapies for solid tumors are often diminished by inadequate metabolic reprogramming and resulting immune evasion in cancer.
Researchers at Stanford have developed a method to direct T cell fate toward the T stem cell memory (TSCM) phenotype during ex vivo expansion for adoptive cell transfer (ACT) therapies.